In short
Clinical trials are investigating Treprostinil in several lung diseases, including pulmonary arterial hypertension and fibrotic lung disease. These studies look at whether Treprostinil can improve outcomes, slow worsening, and remain safe in different patient groups. They also compare Treprostinil with placebo or with other treatment strategies.
Key points
- Clinical trials of Treprostinil are studying several serious lung diseases, especially pulmonary arterial hypertension and different forms of lung fibrosis. Most of the studies are Phase 3 trials, which means they are late-stage studies looking at both benefit and safety. The main goals are to see whether Treprostinil can improve lung function, exercise ability, and time to disease worsening. Some trials compare Treprostinil with placebo, while one study compares an initial triple therapy plan with double oral therapy in pulmonary arterial hypertension. The target populations include people with idiopathic pulmonary fibrosis, progressive pulmonary fibrosis, fibrotic lung disease, and pulmonary hypertension linked to interstitial lung disease.
Clinical trials overview
The trial data shows that Treprostinil is being studied in several different lung conditions, not just one disease. These studies are looking at whether it can help people with pulmonary arterial hypertension, idiopathic pulmonary fibrosis, progressive pulmonary fibrosis, fibrotic lung disease, and pulmonary hypertension associated with interstitial lung disease.
Most of the trials in the source data are Phase 3 studies, which are late-stage trials that test how well a treatment works and how safe it is in larger groups. One study is listed as Low Intervention, which means the study plan uses a lower level of intervention than a typical drug trial, but it is still testing treatment effects.
Pulmonary arterial hypertension study
The TripleTRE study is a randomized trial in people with pulmonary arterial hypertension (group I). It compares initial triple therapy, which includes oral ERA, oral PDE-5i, and parenteral Treprostinil, with initial double oral therapy using oral ERA and oral PDE-5i.
This study is designed to see whether starting with the triple treatment plan can improve risk status compared with the double oral plan. Risk status is a way to judge how serious the disease is and how likely it is to get worse.
The main outcome is whether a person becomes a therapy-responder or a therapy-non-responder between week 12 and week 48. A responder is someone who reaches low-risk status between week 24 and week 48, while a non-responder is someone who has disease worsening, needs extra medication, changes treatment because it is not working well enough, or does not reach low-risk status by week 48.
Fibrotic lung disease studies
One Phase 3 extension study is looking at people with fibrotic lung disease and is focused on the long-term safety and tolerability of inhaled Treprostinil. The study is large, with an enrollment of 1,843 participants, and it is authorised.
This study measures several signs of benefit and disease control, including change in absolute FVC, time to clinical worsening, time to acute exacerbation, overall survival, change in % predicted FVC, K-BILD score, N-terminal pro-brain natriuretic peptide, DLCO, and resting supplemental oxygen use. It also checks safety using adverse events, serious adverse events, laboratory tests, vital signs, oxygen saturation, and electrocardiograms.
Progressive pulmonary fibrosis study
The TETON-PPF study is a randomized, double-blind, placebo-controlled, multinational Phase 3 trial in people with progressive pulmonary fibrosis. Double-blind means that neither the patient nor the study team knows who receives the study drug or placebo during the trial.
The main goal is to compare inhaled Treprostinil with placebo for the change in absolute FVC from baseline to week 52. FVC is a lung function test that shows how much air a person can breathe out after a deep breath.
Pulmonary hypertension and interstitial lung disease study
The 2024-517943-29-00 study tests a new inhaled treatment called L606 in people with pulmonary hypertension associated with interstitial lung disease, also called WHO Group 3. The trial is Phase 3, authorised, and plans to enroll 343 participants.
Although the study is described as testing L606, the intervention list includes Treprostinil Liposome and placebo inhalation suspension. The main outcome is the change from baseline to week 16 in 6-minute walk distance, which checks how far a person can walk in 6 minutes.
What the trials measure
The trial data uses a mix of efficacy and safety endpoints.
Efficacy means how well the treatment works, and safety means how well it is tolerated and what unwanted medical problems may happen during the study.
- FVC is used in the IPF and PPF studies to see whether lung function changes over time.
- 6-minute walk distance is used to measure exercise ability in the WHO Group 3 study.
- Clinical worsening includes serious signs such as death, respiratory hospitalization, or a major decline in lung function.
- Overall survival checks whether people are alive during the study period.
- Safety checks include side effects, lab tests, vital signs, oxygen saturation, and ECGs.
What participation means
These trials are not open to everyone with breathing problems; each study has specific target populations based on the diagnosis. For example, one study is for group I pulmonary arterial hypertension, while others focus on fibrotic lung disease, idiopathic pulmonary fibrosis, progressive pulmonary fibrosis, or pulmonary hypertension linked to interstitial lung disease.
The studies also use different treatment plans, such as inhaled Treprostinil, parenteral Treprostinil, placebo, or combination therapy with other pulmonary hypertension medicines.
Because the trials measure both benefit and safety, they are designed to show not only whether Treprostinil may help, but also whether the treatment plan can be used over time in the studied groups.